Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Teva Pharm CEO: Not too late to launch Humira biosimilar in 2024
12:26pm, Wednesday, 02'nd Aug 2023
Teva Pharmaceutical Industries , will still pursue launching a biosimilar for arthritis drug Humira next year despite a crowded marketplace, chief executive Richard Francis said on Wednesday.
Teva CEO Richard Francis on Q2 earnings beat
12:11pm, Wednesday, 02'nd Aug 2023
Teva CEO Richard Francis joins 'Squawk on the Street' to discuss their Q2 earnings, what's next for the company, and more.
Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries Ltd. (TEVA) Q2 Earnings
11:57am, Wednesday, 02'nd Aug 2023
The headline numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metr
Teva Pharmaceutical Q2 profit tops estimates, Huntington's drug sales jump
07:22am, Wednesday, 02'nd Aug 2023
Teva Pharmaceutical Industries reported higher than expected second-quarter profit boosted by a jump in sales of its Austedo treatment for Huntington's Disease.
Teva Pharmaceuticals and Alvotech expand biosimilars partnership
08:47am, Monday, 24'th Jul 2023
Teva Pharmaceuticals Industries Ltd. TEVA, +0.47% and Alvotech ALVO, +0.51% announced Monday that they are expanding their collaboration in the U.S. biosimilars market.
Teva Pharmaceutical's Remarkable Growth In 2023: A Success Story
10:43am, Thursday, 20'th Jul 2023
On August 2, 2023, Teva Pharmaceutical, one of the world's top generic drug manufacturers, will publish its financial report for the second quarter of 2023. The company has launched generic versions o
Teva Pharmaceuticals upgraded with improving product mix set to bolster gross margins
02:59pm, Thursday, 06'th Jul 2023
Analysts at UBS have upgraded their rating on Teva Pharmaceuticals, a manufacturer of generic pharmaceuticals, to ‘Neutral' from ‘Sell' citing a now balanced risk/reward profile. They also raised
Teva considers sale of its active ingredients unit: Bloomberg
11:03am, Thursday, 06'th Jul 2023
Shares of Teva are fluctuating after a report from Bloomberg that the company is considering a sale of its active ingredients business. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down t
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
04:30pm, Wednesday, 05'th Jul 2023
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2023 financial results on Wednesda
5 Well-Known Buy-Rated Stocks Under $10 Could Explode Higher in July
06:15am, Saturday, 24'th Jun 2023
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
3 Bargain Stocks to Buy on the Dip
06:10am, Saturday, 17'th Jun 2023
Bristol Myers Squibb stock is too cheap to ignore. Pfizer has more good news on the way than meets the eye.
NY AG approves $17.3 billion opioid settlement with CVS, Walgreens, Teva and AbbVie's Allergan
10:09am, Friday, 09'th Jun 2023
New York Attorney General Letitia James announced Friday the final approval of $17.3 billion in national settlement agreements with drug-store chains CVS Health Corp. CVS, and Walgreens Boots Alliance
Teva Pharmaceutical settles $193M opioid suit with the state of Nevada
12:34pm, Thursday, 08'th Jun 2023
Teva Pharmaceutical Industries (NASDAQ:TEVA) has agreed to pay the state of Nevada $193 million to settle claims that its marketing efforts helped fuel opioid addiction, the state announced Wednesday.
Teva concludes nationwide opioid settlement agreement, reaches separate settlement with Nevada
08:53am, Thursday, 08'th Jun 2023
Teva Pharmaceuticals TEVA, +2.07% announced Thursday that it has resolved its nationwide settlement agreement related to opioid claims brought by states and reached a separate settlement with the stat
Teva to pay Nevada $193 million over role in opioid epidemic
05:15pm, Wednesday, 07'th Jun 2023
Teva Pharmaceutical Industries on Wednesday agreed to pay Nevada $193 million to settle claims that its marketing practices fueled opioid addiction, the state announced.
